Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leukemia, Eosinophilic, Acute

ClinicalTrials.gov lists 59 trials for Leukemia, Eosinophilic, Acute or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 20.

MeSH D015472 Neoplasms Neoplasm C04 C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 22 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 17 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 6 Phase 4 Phase 4 1 Not applicable Not applicable 1 Observational Observational 9 Phase 1 Phase 1 22 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 17 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 6 Phase 4 Phase 4 1 Not applicable Not applicable 1 Observational Observational 9

Trials per phase (log scale)

59 of the 59 trials are tagged with Leukemia, Eosinophilic, Acute itself; the rest are tagged with a narrower condition beneath it.

Get the Leukemia, Eosinophilic, Acute report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leukemia, Eosinophilic, Acute trials start? (14)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 10

1998: 4 trials (Phase 4 1, Phase 2 2, Phase 1 1) 1999: 1 trials (Phase 1 1) 2000: 2 trials (Phase 3 1, Phase 2 1) 2001: 3 trials (Phase 2 2, Phase 1 1) 2002: 1 trials (Phase 1 1) 2004: 10 trials (Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 4) 2005: 9 trials (Phase 3 1, Phase 2 1, Phase 1 7) 2006: 9 trials (Observational 2, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 2) 2007: 2 trials (Phase 3 1, Phase 1 1) 2008: 5 trials (Not applicable 1, Phase 3 1, Phase 2 3) 2010: 5 trials (Observational 1, Phase 2 1, Phase 1 3) 2011: 4 trials (Observational 4) 2012: 3 trials (Observational 2, Phase 1 1) 2014: 1 trials (Phase 2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2014 1
2012 3
2011 4
2010 5
2008 5
2007 2
2006 9
2005 9
2004 10
2002 1

Showing 10 of 14 earlier years.

Start your 14-day trial Email me all 14 earlier years as a PDF

No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 59 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leukemia, Eosinophilic, Acute trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 22
Phase 1/2 1
Phase 2 17
Phase 2/3 2
Phase 3 6
Phase 4 1
Not applicable 1
Observational 9

How many Leukemia, Eosinophilic, Acute trials are recruiting? (4)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Active, not recruiting 1
Completed 45
Terminated 7
Unknown status 6

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leukemia, Eosinophilic, Acute trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 20
Children's Oncology Group 5
SWOG Cancer Research Network 4
European Organisation for Research and Treatment of Cancer - EORTC 2
Vion Pharmaceuticals 2

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Leukemia, Eosinophilic, Acute? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
CLOFARABINE 5
Tipifarnib 5
Cytoxan 4
Mitoxantrone 4
Sorafenib 3

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cytarabine IT 23
Daunorubicine 8
Etoposid 8
Idarubicina 7
Filgrastime (G-CSF) 6

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leukemia, Eosinophilic, Acute trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Hemoglobin decreased 302 1
Platelet count decreased 301 1
Neutrophil count decreased 291 1
Febrile neutropenia 271 7
Fatigue 195 2

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages